Dexamethasone for the treatment of hospitalised patients with COVID-19

Austrian Institute for Health Technology Assessment (AIHTA)
Record ID 32018001152
Authors' objectives: This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO, an overview of available evidence and Evidence gaps of dexamethasone in the target patient populations with relevant comparators.
Project Status: Completed
Year Published: 2020
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
MeSH Terms
  • COVID-19
  • Dexamethasone
  • Drug Therapy
  • SARS-CoV-2
  • Coronavirus Infections
Organisation Name: European Network for Health Technology Assessment
Contact Email:
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.